SYRS News and Press, Syros Pharmaceuticals Inc. From 08/09/22

Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q2 GAAP EPS of -$0.54 misses by $0.13 . Revenue of $6.28M (+21.7% Y/Y) beats by $1.5M . Cash and Financial Guidance Cash, cash equivalents and marketable securities as of June 30, 2022 were $86.3 milli...

Preliminary Data From First Cross-Over Study Directly Comparing PK of SY-2101 to the Approved IV Dose of ATO Demonstrates Comparable PK Exposures; Expect to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Definitive Merger Agreement with TYME Technologies and Concurr...

Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has ...

Clinical-stage biotech Syros Pharmaceuticals ( NASDAQ: SYRS ) on Wednesday that the European Medicines Agency (EMA) issued a positive opinion for an orphan drug designation for its lead asset tamibarotene in myelodysplastic syndrome (MDS). The shares of micro-cap biotech sur...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan drug designation for tamibarotene for the...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and pro...

Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...

Development stage biotech firms Syros Pharmaceuticals ( SYRS ) and Tyme Technologies ( NASDAQ: TYME ) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros ( SYRS ) will acquire Tyme ( TYME ). Tyme ( TYME )...

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial o...

Syros Pharmaceuticals, Inc. (SYRS) Q1 2022 Earnings Conference Call May 16, 2022, 08:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and IR Nancy Simonian - CEO Jason Haas - CFO David Roth - Chief Medical Officer Kristin Stephens - Chief Development Office E...